The implant is less invasive and quick to insert. It involves fixing two adjacent vertebra by compression around a previously-inserted interbody cage.
“Following an examination of the product’s clinical data — almost 5,000 units have already been implanted outside the United States since the product’s launch in 2006 — the FDA has approved our cervical staple in the US market for the same indications as cervical plates. This approval has given rise to the creation of a new product code in the FDA’s internal classification, giving the product a unique position on the spinal column fixation device market,” said Denys Sournac, chairman and CEO of MEDICREA.
More Articles on Devices:
Revenue up 3%, new strategy revealed: 10 key notes from Smith & Nephew’s 2Q financial report
Smith & Nephew to move some production to China
K2M’s new spine system launches, clearances: 3 updates
